

References

I-56

1. Society for Maternal Fetal Medicine. The choice of progestogen for the prevention of preterm birth in women with singleton pregnancy and prior preterm pirth. *Am J Obstet Gyencol.* 2017;216(3):B11-B13.
2. Rundell K & Panchal B. Preterm labor: prevention and management. *Am Fam Physician.* 2017;95(6):366-372.
3. Clinical Pharmacology™ Compendium. 2021. Tampa FL: Gold Standard, Inc. Hydroxyprogesterone Caproate.
4. American College of Obstetricians and Gynecologists'. Practice advisory: Clinical guidance for integration of the findings of the PROLONG study: progestin's role in optimizing neonatal gestation. 2019.
5. Society for Maternal-Fetal Medicine Publications Committee. SMFM statement: Use of 17-alpha hydroxyprogesterone caproate for prevention of recurrent preterm birth. 2019.
6. Blackwell SC, Gyamfi-Bannerman C, Biggio JR, et al. 17-OHPC to prevent recurrent preterm birth in singleton gestations (PROLONG Study): A mulitcenter, international, randomized double-blind trial. *Am J Perinatol.* 2020;37(02):127-136.
7. Stewart L, Simmonds M, Duley L, et al. Evaluating Progestogens for Preventing Preterm birth International Collaborative (EPPPIC): Meta-analysis of individual participant data from randomized controlled trials. *Lancet* 2021; 397(10280):1183-94.
8. Makena (hydroxyprogesterone caproate), injection, for intramuscular or subcutaneous use [package insert]. AMAG Pharmaceuticals, Inc. Waltham, MA. 2011 Revised 2/2018.
9. Society for Maternal-Fetal Medicine Publications Committee. SMFM statement: Response to EPPPIC and considerations for the use of progestogens for the prevention of preterm birth. 2021.
10. Hydroxyprogesterone caproate In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated December 13, 2011.